Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review
Neerav Monga, Constantine Tam, Jamie Garside, Matthew S Davids, Katherine Ward, Joan Quigley, Lori Parisi, Christoph Tapprich
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | ELSEVIER SCIENCE INC | Published : 2021
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma (NHL) with a median overall survival (OS) of approximately 3-5 years. Systematic literature reviews (SLRs) identified efficacy and safety data for first-line therapies, reported in randomised controlled trials (RCTs) and non-randomised interventional studies (NRISs). Nine and 20 independent studies were included in the RCT and NRISs SLRs, respectively. Differences in the regimens and patient outcomes varied according to patient age and suitability for autologous stem cell transplantation (ASCT). In elderly patients ineligible for transplant, OS ranged from 40 months to 69.6 months. In young transplant-eligible patients, OS r..View full abstract
The authors would like to thank Peter O'Donovan (ICON Plc) and Iain Fotheringham (ICON Plc) for medical writing support in the development of this manuscript. Funding for this work was provided by Janssen.